PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9815816-0 1997 Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Vitamin D 16-25 kallikrein related peptidase 3 Homo sapiens 82-107 24190367-9 2014 CONCLUSION: The association between PSA and sUV may only be evident at low solar UV irradiance, and this effect may be independent of serum vitamin D levels. Vitamin D 140-149 kallikrein related peptidase 3 Homo sapiens 36-39 31038028-11 2018 Current evidence suggests that vitamin D supplementation in conjunction with standard of care (e.g. chemotherapy, radiation therapy) may confer clinical benefits such as a decrease in serum PSA levels and VDR expression but further research is required to ascertain these results. Vitamin D 31-40 kallikrein related peptidase 3 Homo sapiens 190-193 26991691-3 2016 OBJECTIVE: We examined whether serum vitamin D concentration was associated with sex steroid hormone and PSA concentrations in a cross-sectional analysis of men in the National Health and Nutrition Examination Surveys (NHANES). Vitamin D 37-46 kallikrein related peptidase 3 Homo sapiens 105-108 9207192-1 1997 In addition to suppressing prostate cell growth, vitamin D also up-regulates the expression of androgen receptor (AR) and prostate-specific antigen (PSA). Vitamin D 49-58 kallikrein related peptidase 3 Homo sapiens 122-153 33213976-14 2021 CONCLUSIONS: The results of our study support the effect of vitamin D in reducing prostate volume and PSA levels, and in improving BPH symptoms. Vitamin D 60-69 kallikrein related peptidase 3 Homo sapiens 102-105 33061877-2 2020 We tested the hypothesis that vitamin D levels would have an impact on prostate specific antigen (PSA) levels. Vitamin D 30-39 kallikrein related peptidase 3 Homo sapiens 71-96 33061877-2 2020 We tested the hypothesis that vitamin D levels would have an impact on prostate specific antigen (PSA) levels. Vitamin D 30-39 kallikrein related peptidase 3 Homo sapiens 98-101 33061877-5 2020 The independent effect of vitamin D levels and age on PSA levels was determined with logistic regression. Vitamin D 26-35 kallikrein related peptidase 3 Homo sapiens 54-57 30522147-4 2019 In the present study, PubMed, Scopus, ISI Web of Science, and Google Scholar were searched up to September 2017 for trials that evaluated the effect of vitamin D supplementation on prostate specific antigen (PSA) response, mortality, and its possible side effects in participants with prostate cancer. Vitamin D 152-161 kallikrein related peptidase 3 Homo sapiens 181-206 30522147-4 2019 In the present study, PubMed, Scopus, ISI Web of Science, and Google Scholar were searched up to September 2017 for trials that evaluated the effect of vitamin D supplementation on prostate specific antigen (PSA) response, mortality, and its possible side effects in participants with prostate cancer. Vitamin D 152-161 kallikrein related peptidase 3 Homo sapiens 208-211 30522147-8 2019 Single arm trials revealed that vitamin D supplementation had a modest effect on PSA response proportion: 19% of those enrolled had at least a 50% reduction in PSA by the end of treatment (95% CI: 7% to 31%; p=0.002). Vitamin D 32-41 kallikrein related peptidase 3 Homo sapiens 81-84 30522147-8 2019 Single arm trials revealed that vitamin D supplementation had a modest effect on PSA response proportion: 19% of those enrolled had at least a 50% reduction in PSA by the end of treatment (95% CI: 7% to 31%; p=0.002). Vitamin D 32-41 kallikrein related peptidase 3 Homo sapiens 160-163 30522147-9 2019 Although before-after studies showed that vitamin D increases the PSA response proportion, it does not seem that patients with prostate cancer benefit from high dose vitamin D supplementation and it should not be recommended for the treatment. Vitamin D 42-51 kallikrein related peptidase 3 Homo sapiens 66-69 24974387-0 2014 Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. Vitamin D 25-34 kallikrein related peptidase 3 Homo sapiens 39-42 22955340-0 2013 Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. Vitamin D 38-47 kallikrein related peptidase 3 Homo sapiens 107-132 22955340-2 2013 We examined whether the measures of vitamin D were associated with prostate-specific antigen (PSA) doubling time in men undergoing active monitoring. Vitamin D 36-45 kallikrein related peptidase 3 Homo sapiens 67-98 19426197-1 2009 OBJECTIVE: To determine the effectiveness of vitamin D therapy in patients with asymptomatic, prostate-specific antigen (PSA)-progression of prostate cancer. Vitamin D 45-54 kallikrein related peptidase 3 Homo sapiens 94-125 19426197-3 2009 Vitamin D therapy was discontinued on disease progression as assessed by symptoms or serum PSA increase. Vitamin D 0-9 kallikrein related peptidase 3 Homo sapiens 91-94 19426197-4 2009 The response to therapy was judged from changes in PSA level from the pretreatment baseline to 3 months after starting vitamin D therapy. Vitamin D 119-128 kallikrein related peptidase 3 Homo sapiens 51-54 19426197-5 2009 RESULTS: Of the 26 patients, five (20%) responded to vitamin D; the mean (range) reduction in PSA level was 45.3 (15.9-95.1)%, and mean duration of response was 4-5 months. Vitamin D 53-62 kallikrein related peptidase 3 Homo sapiens 94-97 15749627-0 2005 Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Vitamin D 31-40 kallikrein related peptidase 3 Homo sapiens 76-79 16988533-6 2006 The therapeutic implication is that vitamin D supplementation in the range of 2000 IU/d, a dose comparable to the effect of summer, can benefit men monitored for rising PSA. Vitamin D 36-45 kallikrein related peptidase 3 Homo sapiens 169-172 18649741-1 2008 The active form of vitamin D, 1alpha,25-dihydroxyvitamin D (1alpha,25(OH)2D), inhibits proliferation and induces the differentiation of prostate cells in culture, attenuates tumor growth in animal models, and decreases prostate specific antigen (PSA) levels in prostate cancer patients. Vitamin D 19-28 kallikrein related peptidase 3 Homo sapiens 219-250 15749627-3 2005 We investigated the effect of the nutrient vitamin D (cholecalciferol), a biochemical precursor of calcitriol, on PSA levels and the rate of rise of PSA in these patients. Vitamin D 43-52 kallikrein related peptidase 3 Homo sapiens 114-117